Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy

Journal of Thoracic Oncology

Volumn 6, Issue 11, 2011, Pages 1923-1929

  Kao, Steven Chuan Hao ^a,b,c   Klebe, Sonja ^d   Henderson, Douglas W ^d   Reid, Glen ^a,c   Chatfield, Mark ^c   Armstrong, Nicola J ^e,f   Yan, Tristan D ^g   Vardy, Janette ^b,c   Clarke, Stephen ^a,c,h   Van Zandwijk, Nico ^a,c   McCaughan, Brian ^g  

^a Bernie Banton Centre   (Australia)

^b Department of Microbiology and Infectious Diseases   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d FLINDERS MEDICAL CENTRE   (Australia)

^e GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Calretinin; Malignant pleural mesothelioma; Neutrophil to lymphocyte ratio; Prognosis

Indexed keywords

CALRETININ; MONOCLONAL ANTIBODY D2-40;

ACCURACY; ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; GENDER; HEMATOLOGICAL PARAMETERS; HISTOPATHOLOGY; HUMAN; INFLAMMATION; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; NEUTROPHIL; NEUTROPHIL TO LYMPHOCYTE RATIO; OVERALL SURVIVAL; PREDICTOR VARIABLE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

EID: 80054915456     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31822a3740     Document Type: Article

References (31)

1. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397-408. (Pubitemid 41073959)
2. Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for management of malignant pleural mesothelioma. Eur Respir J 2010;35: 479-495.
3. Tsao AS, Wistuba I, Roth JA, et al. Malignant pleural mesothelioma. J Clin Oncol 2009;27:2081-2090.
4. Spirtas R, Connelly RR, Tucker MA. Survival patterns for malignant mesothelioma: the seer experience. Int J Cancer 1988;41:525-530.
5. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21: 2636-2644. (Pubitemid 46606305)
6. Weder W, Kestenholz P, Taverna C, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothe-lioma. J Clin Oncol 2004;22:3451-3457. (Pubitemid 41103650)
7. Weder W, Stahel R, Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007;18:1196-1202. (Pubitemid 47244366)
8. Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol 2006;1:289-295. (Pubitemid 47163979)
9. de Perrot M, Ginsberg R, Payne D, et al. A phase II trial of induction chemotherapy followed by extrapleural pneumonectomy and high-dose hemithoracic radiation for malignant pleural mesothelioma. Lung Cancer 2003;41:S59.
10. Rea F, Marulli G, Bortolotti L, et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results. Lung Cancer 2007;57:89-95. (Pubitemid 46843340)
11. Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneu-monectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:3007-3013.
12. Stahel RA, Weder W, Felip E; ESMO Guidelines Working Group. Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19:ii43-ii44.
13. British Thoracic Society Standards of Care Committee. BTS statement on malignant mesothelioma in the UK, 2007. Thorax 2007;62:ii1-ii19.
14. Yan T, Boyer M, Tin M, et al. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. J Thorac Cardiovasc Surg 2009;138:619-624.
15. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative longterm survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-65. (Pubitemid 29022249)
16. Flores R, Routledge T, Seshan V, et al. The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg 2008; 136:605-610.
17. Husain A, Colby T, Ordonez N, et al. Guidelines for pathologic diagnosis of malignant mesothelioma. A consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009; 133:1317-1331.
18. Klebe S, Nurminen M, Leigh J, et al. Diagnosis of epithelial mesothe-lioma using tree-based regression analysis and a minimal panel of antibodies. Pathology 2009;41:140-148.
19. Kao S, Pavlakis N, Harvie R, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 2010;16:5805-5813.
20. Travis WD, Brambilla E, Muller-Hermelink HK, et al. World Health Organisation Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004.
21. Page D, Fleming I, Fritz A, et al. AJCC Cancer Staging Manual, 6th Ed. New York: Springer, 2002.
22. Bottomley A, Coens C, Efficace F, et al. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? a prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol 2007;25:5770-5776.
23. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998;113:723-731. (Pubitemid 28130949)
24. Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998;16:145-152. (Pubitemid 28041592)
25. Schemper M, Henderson R. Predictive accuracy and explained variation in Cox regression. Biometrics 2000;56:249-255. (Pubitemid 30165116)
26. Lusa L, Miceli R, Mariani L. Estimation of predictive accuracy in survival analysis using R and S-PLUS. Comput Methods Programs Biomed 2007;87:132-137. (Pubitemid 47017494)
27. Rusch V. The Mars trial: resolution of the surgical controversies in mesothelioma? J Thorac Oncol 2009;4:1189-1191.
28. Suster S, Moran C. Tumors of the lungs and pleura. In I Damjanov, F Fan. (Eds.) Cancer Grading Manual. New York: Springer, 2007:23-30.
29. Milano M, Zhang H. Malignant pleural mesothelioma. A population-based study of survival. J Thorac Oncol 2010;5:1841-1848.
30. Cunto-Amesty G, Richards WG, Sugarbaker D, et al. Morphologically-based grading of epithelial malignant pleural mesothelioma (Abstr P10-2). 10th International Conference of the International Mesothelioma Interest Group abstract book 2010;p176. Available at: http://imig.org/wp-content/uploads/2011/ 01/IMIG2010Abstractfinal101227.pdf. Accessed January 25, 2011.
31. Takeshima Y, Inai K, Ishikawa Y, et al. The trial of differentiation grading of epithelioid mesothelioma with reference to its clinicopathological significance (Abstr P10-1). 10th International Conference of the International Mesothelioma Interest Group; 2010; p175. Available at: http://imig.org/wp- content/uploads/2011/01/IMIG2010Abstractfinal101227.pdf. Accessed January 25, 2011.